CV Therapeutics, Inc., headquartered in Palo
Alto, California, is a biopharmaceutical company focused on
applying molecular cardiology to the discovery, development
and commercialization of novel, small molecule drugs for the
treatment of cardiovascular and metabolic diseases. CV
Therapeutics currently has four clinical development drug
candidates and has entered into an agreement with Solvay
Pharmaceuticals, Inc. to co-promote ACEON® (perindopril
erbumine) Tablets for the treatment of hypertension.
